Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Cancers|November 13, 2025
Impact of Anti-HER2 Therapies on Overall Survival in Patients with HER2-Positive Metastatic Breast Cancer: Focusing on Intracranial Efficacy of Emerging TreatmentsDenise Drittone, Claudia Lucci, Luisa Esposito, et al.
Blood|August 19, 2004
p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cellsSimona Pisegna, Gianluca Pirozzi, Mario Piccoli, et al.
Clinical Nutrition (Edinburgh, Scotland)|March 7, 2025
Association between body composition parameters and treatment-related toxicities in patients with metastatic breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitorsGiovanni Imbimbo, Marica Pellegrini, Simone Scagnoli, et al.
Journal of Medical Case Reports|July 3, 2026
Diagnostic challenge of occult ER-positive breast carcinoma within bone marrow indolent B-cell lymphoma and response to CDK4/6 inhibitor: a case reportDenise Drittone, Monica Mariniello, Luisa Esposito, et al.
Cancers|September 27, 2025
Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab DeruxtecanAlessio Molfino, Giovanni Imbimbo, Simona Pisegna, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 22, 2002
Src-dependent Syk activation controls CD69-mediated signaling and function on human NK cellsSimona Pisegna, Alessandra Zingoni, Gianluca Pirozzi, et al.
Diagnostics (Basel, Switzerland)|December 24, 2021
Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line TreatmentsChiara Nicolazzo, Alain Gelibter, Irene Bottillo, et al.
Clinical and Experimental Medicine|April 10, 2024
Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohortFulvia Ceccarelli, Francesco Natalucci, Licia Picciariello, et al.
Critical Reviews in Oncology/Hematology|June 5, 2024
Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatmentsFiorenza Santamaria, Michela Roberto, Dorelsa Buccilli, et al.
The Oncologist|May 14, 2025
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecanAnna Amela Valsecchi, Simona Pisegna, Andrea Antonuzzo, et al.
Pageof 4